

# Transgene

[View the current Transgene Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/10316-Transgene.html)

(<http://www.bioportfolio.com/biocorporate/10316-Transgene.html>)

## Contact Details:

11 rue de Molsheim  
Strasbourg

Tel: 00 33 88 27 91 00

Fax: 00 33 88 27 91 11

Email:

F-67082  
France

TRANSGENE is a leading integrated gene therapy company, dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired and inherited diseases. The Company's proprietary technology platform consists of five vector families including three of viral origin - adenovirus, retrovirus, vaccinia virus - and two of non viral origin - cellular and synthetic vectors.

## Recent Publications by Transgene:



- [Solution structure of the complex of VEK-30 and plasminogen kringle 2.](#)  
*The solution structure of the complex containing the isolated kringle 2...*6th October, 2009  
W.M. Keck Center for Transgene Research, 230 Raclin-Carmichael Hall,- J Struct Biol. 2009 Sep 30. ([DOI Direct Link](#))
- [The protein C pathway and pathologic processes.](#)  
*Alterations in expression of protein C (PC) pathway components have been...*28th July, 2009  
W. M. Keck Center for Transgene Research, and Department of Chemistry and- J Thromb Haemost. 2009 Jul;7 Suppl 1:140-5. ([DOI Direct Link](#))
- [Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy.](#)  
*The delivery of stimulatory signals to dendritic cells (DCs) in the tumor...*10th June, 2009  
Molecular Immunology Department, Transgene, Strasbourg, France.- Cancer Gene Ther. 2009 Apr;16(4):310-9. Epub 2008 Oct 24. ([DOI Direct Link](#))
- [ADP-ribosylation factor 6 regulates tumorigenic and invasive properties in vivo.](#)  
*This study shows that the small GTP-binding protein ADP-ribosylation...*14th May, 2009  
Department of Biological Sciences, Freimann Life Science Center, and W.M.- Cancer Res. 2009 Mar 15;69(6):2201-9. Epub 2009 Mar 10. ([DOI Direct Link](#))

- [The selectivity of conantokin-G for ion channel inhibition of NR2B subunit-containing NMDA receptors is regulated by amino acid residues in the S2 region of NR2B.](#)  
*The conantokins are short, naturally occurring peptides that inhibit ion...* 12th May, 2009  
W.M. Keck Center for Transgene Research and Department of Chemistry and- Neuropharmacology. 2009 Aug;57(2):127-36. Epub 2009 May 8. ([DOI Direct Link](#))
- [Vaccination against hepatitis B and C: towards therapeutic application.](#)  
*This study shows that the small GTP-binding protein ADP-ribosylation...* 7th April, 2009  
Transgene- Int Rev Immunol. 2009;28(1):7-19. ([DOI Direct Link](#))
- [Severe deficiency of coagulation Factor VII results in spontaneous cardiac fibrosis in mice.](#)  
*Mice genetically modified to produce low levels (approximately 1% of...* 21st February, 2009  
W. M. Keck Center for Transgene Research and the Department of Chemistry- J Pathol. 2009 Feb;217(3):362-71. ([DOI Direct Link](#))
- [Plasminogen activator inhibitor-1: the double-edged sword in apoptosis.](#)  
*Plasminogen activator inhibitor type-1 (PAI-1) is a multi-functional...* 13th February, 2009  
W. M. Keck Center for Transgene Research, Department of Chemistry and- Thromb Haemost. 2008 Dec;100(6):1029-36.
- [N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein.](#)  
*The effects of a synthetic apoE peptide, viz., residues 133-149...* 17th December, 2008  
W.M. Keck Center for Transgene Research, Department of Chemistry and- Neuropharmacology. 2008 Aug;55(2):204-14. Epub 2008 May 24. ([DOI Direct Link](#))
- [Gene transfer into canine myoblasts.](#)  
*We have developed and characterized cultures of healthy and dystrophic...* 13th November, 2008  
TRANSGENE S.A., 11 rue de Molsheim, 67082, Strasbourg Cedex, France.- Cytotechnology. 1999 Jul;30(1-3):181-9. ([DOI Direct Link](#))
- [A single plasmid transfection that offers a significant advantage associated with puromycin selection in Drosophila Schneider S2 cells expressing heterologous proteins.](#)  
*The Drosophila Schneider S2 (S2) Expression System enables expression of...* 13th November, 2008  
W.M. Keck Center for Transgene Research, University of Notre Dame, 235- Cytotechnology. 2008 May;57(1):45-9. Epub 2008 Feb 8. ([DOI Direct Link](#))
- [Clinical development of MVA-based therapeutic cancer vaccines.](#)  
*Tumor-associated antigens (TAAs) have been formulated into vaccines that...* 24th October, 2008  
Transgene SA,- Expert Rev Vaccines. 2008 Sep;7(7):889-93. ([DOI Direct Link](#))
- [Wnt signaling in renal cancer.](#)  
*About one fourth of people diagnosed with kidney cancer in 2007, are...* 17th October, 2008  
W.M. Keck Center for Transgene Research, Department of Chemistry and- Curr Drug Targets. 2008 Jul;9(7):591-600.
- [A missense mutation in the sodium phosphate co-transporter Slc34a1 impairs phosphate homeostasis.](#)  
*The sodium phosphate co-transporters Npt2a and Npt2c play important roles...* 8th October, 2008  
W.M. Keck Center for Transgene Research and the Department of Chemistry- J Am Soc Nephrol. 2008 Sep;19(9):1753-62. Epub 2008 Jun 11. ([DOI Direct Link](#))
- [Endothelial progenitor cells: new perspectives and applications in cardiovascular therapies.](#)  
*For over 10 years, bone marrow-derived endothelial progenitor cells (EPCs)...* 17th July, 2008  
Center for Transgene Technology and Gene Therapy, Flanders Institute for- Expert Rev Cardiovasc Ther. 2008 Jun;6(5):687-701. ([DOI Direct Link](#))

## Press Releases on Transgene:

<a href="#">New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report</a>	7th July, 2009	Reportlinker	NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Hepatitis C Virus And Therapeutics Market <a href="http://www.reportlinker.com/p0119497/World">http://www.reportlinker.com/p0119497/World</a>
<a href="#">Caprion Proteomics Inc. and Applied Bioystems Work Together to Accelerate Protein Biomarker Verification and Validation</a>	28th May, 2009	Caprion Proteomics Inc.	Combination of industry-leading services with unique QTRAP(R) technology MONTREAL, May 28 /PRNewswire/ -- Caprion Proteomics Inc. today announced that it is working with Applied Biosystems, a
<a href="#">The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases</a>	18th May, 2009	The Institut Pasteur and Merieux Alliance	PARIS, May 18 /PRNewswire/ -- The Institut Pasteur and Merieux Alliance have signed a letter of intent for a long-term research partnership. The Institut Pasteur and Merieux Alliance (which
<a href="#">The Institut Pasteur and MÃ©rieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases</a>	18th May, 2009		PARIS, May 18 /PRNewswire/ -- The Institut Pasteur and MÃ©rieux Alliance have signed a letter of intent for a long-term research partnership. The Institut Pasteur and MÃ©rieux Alliance (which
<a href="#">Covance Purchases Equity Stake in Caprion Proteomics</a>	16th December, 2008	Covance Inc.	- New Biomarker VP Appointed - Biomarker Center of Excellence Established in Greenfield, Indiana PRINCETON, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), a leading provider of

## BioNews Results for Transgene



- [Transgene initiates enrollment in Phase I cancer trial](#)  
Individual.com: Nov 9 2009 2:17PM Matching: transgene

- [Transgene: First Patient enrolled in Phase I Trial of TG4023 for PharmiWeb: Nov 6 2009 5:33AM Matching: transgene](#)
- [Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours Pharma Live: Nov 5 2009 11:38AM Matching: transgene](#)
- [Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours Therapeutics Daily: Nov 5 2009 1:49AM Matching: transgene](#)
- [TRANSGENE : First patient enrolled in Phase I trial of TG4023 for the treatment of liver tumours Individual.com: Nov 5 2009 7:31AM Matching: transgene](#)
- [Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours Bionity.com: Nov 5 2009 3:57PM Matching: transgene](#)
- [Transgene: Cash position of ,72.9 million as of September 30, 2009 Pharma Live: Oct 19 2009 8:05PM Matching: transgene](#)
- [TRANSGENE: Cash position of E72.9 million as of September 30, 2009 Individual.com: Oct 19 2009 3:57PM Matching: transgene](#)

### Transgene Clinical Trials:



- [Trial of TG4023 Combined With Flucytosine in Liver Tumors](#)

### Transgene Patents:



- 6326350- [Transferrin receptor subunit proteins of Neisseria meningitidis](#)
- 6555377- [Process for production of mammalian cell lines](#)
- 6569677- [Modified adenoviral fiber and target adenoviruses](#)
- 6582694- [Method for preparing a viral aerosol](#)
- 6596533- [Mutant having uracil phosphoribosyl transferase activity](#)
- 6656734- [Compositions for the delivery of polynucleotides to cells](#)
- 6692956- [Recombinant adenoviral vectors](#)
- 6703226- [Expression of a foamy virus envelope protein](#)
- 6723708- [Use of lithium \(Li+\) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy](#)
- 6740511- [Modified adenoviral fibre and uses thereof](#)
- 6743781- [Glycerolipid compounds useful for the transfer of an active substance into a target cell](#)
- 6528312- [Use of G-actin for improving transfection of a polynucleotide into a cell](#)
- 6514756- [Human myoblast cell lines and their uses](#)
- 6479290- [Chimeric adenoviral vectors](#)
- 6328956- [Pharmaceutical composition for the treatment or prevention of a malignant tumor](#)

- 6335199- [Lipid compounds and compositions containing same used for the transfer of at least an active substance, in particular a polynucleotide, in a target cell and therapeutic use](#)
- 6344194- [Method for preparing a viral aerosol and its use in gene therapy treatment](#)
- 6346414- [Transposition assembly for gene transfer in eukaryotes](#)
- 6350575- [Helper viruses for the preparation of recombinant viral vectors](#)
- 6372443- [Cassette for expressing a toxoplasma gondii P30 protein](#)
- 6399587- [Recombinant adenoviral vectors comprising a splicing sequence](#)
- 6407178- [Cationic polymers, complexes associating said cationic polymers with therapeutically active substances comprising at least a negative charge, in particular nucleic acids, and their use in gene therapy](#)
- 6451256- [Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicine](#)
- 6475480- [Use of adenoviral E4 reading frames to improve expression of a gene of interest](#)
- 6881724- [Use of magnesium \(Mg<sup>2+</sup>\) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy](#)
- 6884786- [Antitumoral composition based on immunogenic polypeptide with modified cell location](#)
- 7332478- [Antitumoral composition based on immunogenic polypeptide with modified cell location](#)
- 7348014- [Poxvirus with targeted infection specificity](#)
- 7354591- [Poxvirus with targeted infection specificity](#)
- 7378265- [Method of inactivating enveloped viruses in a viral preparation of non-enveloped viruses](#)
- 7393831- [Peptide compositions and their use against HCV](#)
- 7482155- [Chimeric promoters for controlling expression in smooth muscle cells](#)
- 7488482- [Pharmaceutical compositions for treating papillomavirus tumors and infection](#)
- 7534585- [Multifunctional cytokines](#)
- 7560527- [Modified adenovirus fibre and uses](#)
- 7572438- [Mutant having uracil phosphoribosyl transferase activity](#)
- 7264958- [Method for obtaining a purified viral preparation](#)
- 7256036- [Modified adenoviral fiber and target adenoviruses](#)
- 7148341- [AAV DNA comprising helper virus sequences](#)
- 6906041- [Treatment of immune diseases](#)
- 6960469- [Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain](#)
- 7005277- [Defective adenoviruses and corresponding complementation lines](#)
- 7026154- [Method of inactivating enveloped viruses in a viral preparation of non-enveloped viruses](#)
- 7026299- [Connective tissue growth factor-2](#)
- 7033779- [Method for preparing steroids modified by yeast fermentation](#)
- 7049117- [Mutant possessing uracil phosphoribosyl transferase activity](#)
- 7067309- [Defective adenoviruses and corresponding complementation lines](#)
- 7067310- [Method for the preparation of a viral vector by inter-molecular homologous recombination](#)
- 7118754- [Pharmaceutical composition for treating papillomavirus tumors and infection](#)
- 7608267- [Multifunctional cytokines](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership

username and password

- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

